355 related articles for article (PubMed ID: 30981835)
21. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.
Gowrishankar K; Birtwistle L; Micklethwaite K
Mamm Genome; 2018 Dec; 29(11-12):739-756. PubMed ID: 29987406
[TBL] [Abstract][Full Text] [Related]
22. Chimeric antigen receptor T cells: a novel therapy for solid tumors.
Yu S; Li A; Liu Q; Li T; Yuan X; Han X; Wu K
J Hematol Oncol; 2017 Mar; 10(1):78. PubMed ID: 28356156
[TBL] [Abstract][Full Text] [Related]
23. [Cancer immunotherapy using gene-engineered T cells].
Kageyama S
Rinsho Ketsueki; 2018; 59(2):216-224. PubMed ID: 29515077
[TBL] [Abstract][Full Text] [Related]
24. Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer.
Magee MS; Snook AE
Discov Med; 2014 Nov; 18(100):265-71. PubMed ID: 25425467
[TBL] [Abstract][Full Text] [Related]
25. CRISPR/Cas systems to overcome challenges in developing the next generation of T cells for cancer therapy.
Huang D; Miller M; Ashok B; Jain S; Peppas NA
Adv Drug Deliv Rev; 2020; 158():17-35. PubMed ID: 32707148
[TBL] [Abstract][Full Text] [Related]
26. CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.
Long KB; Young RM; Boesteanu AC; Davis MM; Melenhorst JJ; Lacey SF; DeGaramo DA; Levine BL; Fraietta JA
Front Immunol; 2018; 9():2740. PubMed ID: 30559740
[TBL] [Abstract][Full Text] [Related]
27. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
28. Augmenting engineered T-cell strategies in solid cancers through epigenetic priming.
Nielsen AY; Ormhøj M; Traynor S; Gjerstorff MF
Cancer Immunol Immunother; 2020 Nov; 69(11):2169-2178. PubMed ID: 32648166
[TBL] [Abstract][Full Text] [Related]
29. The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review.
Zhang J; Wang L
Technol Cancer Res Treat; 2019 Jan; 18():1533033819831068. PubMed ID: 30798772
[TBL] [Abstract][Full Text] [Related]
30. Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors.
Harris DT; Kranz DM
Trends Pharmacol Sci; 2016 Mar; 37(3):220-230. PubMed ID: 26705086
[TBL] [Abstract][Full Text] [Related]
31. [Prospect for chimeric antigen receptor-engineered T cell immunotherapy for solid tumors].
Zhou SY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):490-492. PubMed ID: 30060355
[TBL] [Abstract][Full Text] [Related]
32. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
Han C; Kwon BS
Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
[TBL] [Abstract][Full Text] [Related]
33. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
34. Adoptive T-Cell Therapy for Solid Tumors.
Yeku O; Li X; Brentjens RJ
Am Soc Clin Oncol Educ Book; 2017; 37():193-204. PubMed ID: 28561728
[TBL] [Abstract][Full Text] [Related]
35. Overcoming key challenges in cancer immunotherapy with engineered T cells.
Arcangeli S; Mestermann K; Weber J; Bonini C; Casucci M; Hudecek M
Curr Opin Oncol; 2020 Sep; 32(5):398-407. PubMed ID: 32796230
[TBL] [Abstract][Full Text] [Related]
36. Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.
Srivastava S; Riddell SR
J Immunol; 2018 Jan; 200(2):459-468. PubMed ID: 29311388
[TBL] [Abstract][Full Text] [Related]
37. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
Guedan S; Alemany R
Front Immunol; 2018; 9():2460. PubMed ID: 30405639
[TBL] [Abstract][Full Text] [Related]
38. Adoptive T cell therapy: Boosting the immune system to fight cancer.
Leon E; Ranganathan R; Savoldo B
Semin Immunol; 2020 Jun; 49():101437. PubMed ID: 33262066
[TBL] [Abstract][Full Text] [Related]
39. T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors.
Tsimberidou AM; Van Morris K; Vo HH; Eck S; Lin YF; Rivas JM; Andersson BS
J Hematol Oncol; 2021 Jun; 14(1):102. PubMed ID: 34193217
[TBL] [Abstract][Full Text] [Related]
40. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
